Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$45.42 USD

45.42
847,455

-0.09 (-0.20%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $45.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CVS Health Retail Prescription Volume Grows Despite LTC Woes

by Zacks Equity Research

CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.

Cardiovascular Systems Rides on Launches Amid Coronavirus Woes

by Zacks Equity Research

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

Boston Scientific Launches DBS System in Europe Post Approval

by Zacks Equity Research

Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.

Nilanjan Banerjee headshot

3 Low-Beta Stocks to Combat Coronavirus-Induced Choppy Market

by Nilanjan Banerjee

To combat market volatility, it is important to create a portfolio of low-beta stocks.

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

Medtronic Receives FDA's Go Ahead for EFS Study on TTVR

by Zacks Equity Research

Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.

National Vision Banks on Contact Lens Sales Amid Coronavirus Woes

by Zacks Equity Research

National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.

Urmimala Biswas headshot

Coronavirus Test Makers With Scope to Maximize Investor Benefits

by Urmimala Biswas

The surge in new coronavirus infections broadens the scope for antigen and antibody tests.

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

by Zacks Equity Research

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

Henry Schein Partners MouthWatch to Grow in Teledentistry

by Zacks Equity Research

Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.

QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test

by Zacks Equity Research

QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.

BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Henry Schein (HSIC) Enters Into New Dental Deal With Zyris

by Zacks Equity Research

Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy

by Zacks Equity Research

Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.

Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (QGEN) Outperforming Other Medical Stocks This Year?

Boston Scientific's Eluvia Gets CMS' Additional Reimbursement

by Zacks Equity Research

Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.

Why Is Qiagen (QGEN) Up 7.5% Since Last Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.

Athenex's NDA for Breast Cancer Drug Gets Priority Review

by Zacks Equity Research

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg

by Zacks Equity Research

Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.

Medtronic (MDT) Plans Up to $475M of Annual Cost Savings

by Zacks Equity Research

Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.

ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam

by Zacks Equity Research

ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

by Zacks Equity Research

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Phirbo's Product Mix Aids, Global Animal Health Business Ails

by Zacks Equity Research

Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.